Coronary stent Abrax™

polymerdrug eluting

Abrax TM Sirolimus-Eluting Stent System is designed to perform successfully even in the most demanding cases. The combination of Sirolimus’ antiproliferative action coupled with Rontis’ biodegradable polymer and proven balloon catheter ensures effective treatment of clinically difficult lesions with confidence. This essentially means that patients who receive Abrax TMare a lot less likely to need another repeat procedure in the short term. Biodegradable polymer PLGA Uniform and site-specific drug delivery Thin layer 5 μm Complete degradation following the drug release into 6 weeks Eliminating inflammation and stent thrombosis Stent platform Carbon ionized surface for higher biocompatibility and reduced restenosis rateCarbon ionized surface for higher biocompatibility and reduced restenosis rate DATS Technology (Dual Anti-Thrombogenic Stent Technology) MSC Design (Multivariate Stent Cell ) This design offers generous access for ballooning and stenting hemodynamically prominent coronary side-branches in order to optimize intramyocardial blood flow to subendocardial and intramural microvasculature. Intra-cellular “sinusoidal links” Open cell design ensures balance of radial strength and flexibility Enhanced radiopacity Optimal scaffolding as well as stent-to-wall apposition with superior acute gain Balloon catheter platform Lower inflation pressuresLower inflation pressures Homogenizes stent expansion Hydrophilicity lowers friction optimizing deliverability Sirolimus Suppresses neointimal growth without suppressing endothelialization Reduces in-stent restenosis Drug load 2.0μg/mm2